Skip to main content

Table 3 Associations of tumor characteristics with Parkinson’s disease gene mRNA relative expression in NSCLC

From: Status of the Parkinson’s disease gene family expression in non-small-cell lung cancer

Tumor characteristics n (%) PARK1/4 (SCNA)   PARK2(Parkin)   PARK5(UCHL-1)   PARK6(PINK1)   PARK7(DJ-1)   PARK8(LRRK2)   PARK9(ATP13A2)   PARK15(FBXO7)   GBA  
   Means ± SD P   Means ± SD P   Means ± SD P   Means ± SD P   Means ± SD P   Means ± SD P   Means ± SD P   Means ± SD P   Means ± SD P  
Overall 114 (100.00%) 1.475 ± 1.088    3.177 ± 3.646    18.375 ± 15.551    5.465 ± 4.949    2.773 ± 2.336    2.272 ± 2.350    8.356 ± 7.402    1.956 ± 1.783    5.936 ± 4.328   
Gender                             
 Male 72 (63.16%) 1.499 ± 1.099    3.095 ± 3.974    18.349 ± 16.095    5.566 ± 4.993    2.638 ± 2.079    2.336 ± 2.357    8.329 ± 7.751    2.207 ± 1.938    6.472 ± 4.709   
 Female 42 (39.84%) 1.433 ± 1.079 .755a1   3.317 ± 3.044 .756a1   18.419 ± 14.760 .982a1   5.291 ± 4.927 .776a1   3.005 ± 2.733 .422a1   2.161 ± 2.362 .703a1   8.401 ± 6.852 .960a1   1.524 ± 1.398 .500a2   5.016 ± 3.443 .147a2  
Histology                             
 Adenocarcinoma 64 (56.14%) 1.584 ± 1.080    4.900 ± 4.200    18.383 ± 14.360    5.422 ± 5.595    3.085 ± 2.710    2.346 ± 2.241    8.904 ± 7.890    2.125 ± 1.945    6.857 ± 4.274   
 Squamous cell carcinoma 50 (44.86%) 1.367 ± 1.116 .303b1   1.202 ± 1.043 .000b2   18.784 ± 17.247 .894b1   5.436 ± 3.857 .988b1   2.410 ± 1.823 .005b1   1.901 ± 1.871 .274b1   7.557 ± 6.534 .337b1   1.775 ± 1.617 .311b1   5.642 ± 3.733 .282b1  
Tumor stage                             
 Stage I 36 (31.58%) 1.723 ± 1.371 .280c1 I–II 5.403 ± 5.442 .040c2 I–II 22.808 ± 18.141 .410c2 I–II 7.404 ± 6.642 .995c1 I–II 4.074 ± 3.377 .003c2 I–II 1.631 ± 1.391 .040c2 I–II 9.608 ± 9.410 .427c2 I–II 3.240 ± 2.546 .070c2 I–II 6.440 ± 5.055 .450c1 I–II
 Stage II 53 (46.49%) 1.457 ± 0.936 .176c1 II–III 2.217 ± 1.783 .598c1 II–III 14.625 ± 11.716 3.27c2 II–III 5.362 ± 4.101 .010c2 II–III 1.894 ± 0.743 .105c2 II–III 3.306 ± 2.880 .000c2 II–III 6.626 ± 5.645 .180c1 II–III 1.567 ± 0.818 .000c2 II–III 5.700 ± 4.131 .098c1 II–III
 Stage III 25 (21.93%) 1.155 ± 0.854 .720c1 I–III 2.001 ± 1.278 .130c1 I–III 19.939 ± 17.271 .538c2 I–III 2.891 ± 1.406 .003c2 I–III 2.765 ± 1.904 .215c2 I–III 1.002 ± 1.904 .100c2 I–III 10.198 ± 6.880 .790c1 I–III 0.930 ± 0.398 .000c2 I–III 5.714 ± 3.663 .542c1 I–III
  1. I–II means the compare between stages I and II, II–III means the compare between stages II and III, I–III means the compare between stages I and III
  2. a: Test for equality of medians between different gene relative expression and different sex: a1two-sided Student’s t-test; a2two-sided Wilcoxon rank sum test
  3. b: Test for equality of medians between different gene relative expression and different tumor histology: b1two-sided Student’s t-test; b2two-sided Wilcoxon rank sum test
  4. c: Test for equality of medians between different gene relative expression and different tumor stage: c1two-sided Student’s t-test; c2two-sided Wilcoxon rank sum test